Have your own idea? Try our Stock Screener
Over the last 7 days, the Biotech industry has dropped 2.1%, driven by pullbacks in Regeneron Pharmaceuticals and Alnylam Pharmaceuticals of 2.7% and 9.4%, respectively. On the other hand Vaxcyte is actually up 40%. Over the past 12 months, the industry was up 13%. Looking forward, earnings are forecast to grow by 30% annually.
Has the U.S. Biotech Industry valuation changed over the past few years?
Date | Market Cap | Revenue | Earnings | PE | Absolute PE | PS |
---|---|---|---|---|---|---|
Wed, 04 Sep 2024 | US$909.4b | US$113.1b | -US$35,700,641,712.66 | 23x | -25.5x | 8x |
Fri, 02 Aug 2024 | US$1.2t | US$165.2b | -US$29,241,766,364.50 | 30.6x | -42x | 7.4x |
Sun, 30 Jun 2024 | US$1.1t | US$164.4b | -US$27,988,781,321.07 | 28.5x | -41x | 7x |
Tue, 28 May 2024 | US$1.1t | US$164.6b | -US$26,662,546,931.62 | 27.2x | -42.2x | 6.8x |
Thu, 25 Apr 2024 | US$1.1t | US$164.1b | -US$23,434,274,940.24 | 20.4x | -46.7x | 6.7x |
Sat, 23 Mar 2024 | US$1.2t | US$164.3b | -US$23,951,750,761.50 | 21.3x | -48.5x | 7.1x |
Mon, 19 Feb 2024 | US$1.2t | US$169.1b | -US$20,519,191,458.58 | 15.7x | -56.9x | 6.9x |
Wed, 17 Jan 2024 | US$1.4t | US$204.7b | -US$22,509,124,769.00 | 18.9x | -63.9x | 7x |
Fri, 15 Dec 2023 | US$1.3t | US$204.8b | -US$22,109,997,154.00 | 19.2x | -61.1x | 6.6x |
Sun, 12 Nov 2023 | US$1.2t | US$204.5b | -US$22,004,263,459.00 | 18.5x | -54.5x | 5.9x |
Tue, 10 Oct 2023 | US$1.3t | US$207.4b | -US$13,078,903,969.00 | 17.1x | -96.1x | 6.1x |
Thu, 07 Sep 2023 | US$1.3t | US$207.5b | -US$12,633,134,897.00 | 16.9x | -100.5x | 6.1x |
Sat, 05 Aug 2023 | US$1.3t | US$210.2b | -US$10,152,777,050.00 | 15.6x | -124.1x | 6x |
Mon, 03 Jul 2023 | US$1.1t | US$186.2b | -US$16,042,400,813.00 | 13.7x | -70x | 6x |
Wed, 31 May 2023 | US$1.1t | US$185.9b | -US$15,975,506,164.00 | 11.3x | -69.7x | 6x |
Fri, 28 Apr 2023 | US$1.1t | US$198.5b | -US$3,342,494,771.00 | 13.1x | -342.6x | 5.8x |
Sun, 26 Mar 2023 | US$1.1t | US$199.3b | -US$3,673,370,952.00 | 13.4x | -308.5x | 5.7x |
Tue, 21 Feb 2023 | US$1.2t | US$202.6b | -US$118,851,937.00 | 16.5x | -9707x | 5.7x |
Thu, 19 Jan 2023 | US$1.2t | US$203.6b | US$1.8b | 14.5x | 661.6x | 5.7x |
Sat, 17 Dec 2022 | US$1.2t | US$203.3b | US$1.6b | 14.4x | 709.9x | 5.7x |
Mon, 14 Nov 2022 | US$1.1t | US$202.2b | US$1.1b | 14.6x | 1002.6x | 5.5x |
Wed, 12 Oct 2022 | US$1.0t | US$206.0b | US$5.4b | 15.3x | 191.6x | 5x |
Fri, 09 Sep 2022 | US$1.1t | US$206.2b | US$6.1b | 14.9x | 177.3x | 5.2x |
Sun, 07 Aug 2022 | US$1.1t | US$211.4b | US$8.8b | 16.7x | 125.7x | 5.3x |
Tue, 05 Jul 2022 | US$1.1t | US$212.1b | US$11.1b | 15.8x | 94.6x | 5x |
Thu, 02 Jun 2022 | US$994.0b | US$212.5b | US$11.1b | 15.2x | 89.4x | 4.7x |
Sat, 30 Apr 2022 | US$1.0t | US$200.4b | US$6.7b | 16.9x | 151.4x | 5.1x |
Mon, 28 Mar 2022 | US$1.3t | US$221.9b | US$11.4b | 18.9x | 111.3x | 5.7x |
Wed, 23 Feb 2022 | US$1.2t | US$216.5b | US$5.6b | 21.8x | 215.6x | 5.6x |
Fri, 21 Jan 2022 | US$1.2t | US$212.0b | US$2.5b | 23x | 501.2x | 5.9x |
Sun, 19 Dec 2021 | US$1.5t | US$211.9b | US$2.8b | 26.1x | 524x | 6.9x |
Tue, 16 Nov 2021 | US$1.5t | US$212.2b | US$3.8b | 26.9x | 383.5x | 6.9x |
Thu, 14 Oct 2021 | US$1.5t | US$196.3b | -US$2,598,648,819.00 | 23.3x | -562x | 7.4x |
Sat, 11 Sep 2021 | US$1.6t | US$196.4b | -US$2,275,254,373.56 | 21.1x | -695.3x | 8.1x |
-695.3x
Which industries have driven the changes within the U.S. Healthcare industry?
US Market | -1.94% | |
Healthcare | 0.15% | |
Biotech | -2.14% | |
Biotech | -2.14% |
Which companies have driven the market over the last 7 days?
Company | Last Price | 7D | 1Y | Valuation | |
---|---|---|---|---|---|
PCVX Vaxcyte | US$110.15 | 39.8% +US$3.5b | 116.0% | PB6.2x | |
GILD Gilead Sciences | US$79.70 | 3.5% +US$3.4b | 6.0% | PE94.1x | |
ABBV AbbVie | US$197.69 | 0.9% +US$3.1b | 35.3% | PE65.9x | |
AMGN Amgen | US$330.51 | 1.1% +US$1.9b | 30.1% | PE56.7x | |
SGEN Seagen | US$228.74 | 4.5% +US$1.8b | 76.5% | PS18.8x |